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Abstract
Background: Brain metastases occur commonly in patients with lung cancer. Small vessel ischemic disease is frequently
found when imaging the brain to detect metastases. We aimed to determine if the presence of small vessel ischemic disease
(SVID) of the brain is protective against the development of brain metastases in lung cancer patients.
Methodology/Principal Findings: A retrospective cohort of 523 patients with biopsy confirmed lung cancer who had
received magnetic resonance imaging of the brain as part of their standard initial staging evaluation was reviewed.
Information collected included demographics, comorbidities, details of the lung cancer, and the presence of SVID of the
brain. A portion of the cohort had the degree of SVID graded. The primary outcome measure was the portion of study
subjects with and without SVID of the brain who had evidence of brain metastases at the time of initial staging of their lung
cancer.109 patients (20.8%) had evidence of brain metastases at presentation and 345 (66.0%) had evidence of SVID. 13.9%
of those with SVID and 34.3% of those without SVID presented with brain metastases (p,0.0001). In a model including age,
diabetes mellitus, hypertension, hyperlipidemia, and tobacco use, SVID of the brain was found to be the only protective
factor against the development of brain metastases, with an OR of 0.31 (0.20, 0.48; p,0.001). The grade of SVID was higher
in those without brain metastases.
Conclusions/Significance: These findings suggest that vascular changes in the brain are protective against the
development of brain metastases in lung cancer patients.
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Introduction
Brain metastases occur in approximately 15% of all cancer
patients [1–3]. Ten –15% of patients with lung cancer have brain
metastases at diagnosis, and an additional 20%–25% develop
brain metastases during their illness [4]. Guidelines suggest brain
imaging at presentation in asymptomatic lung cancer patients with
evidence of locally advanced non-small cell carcinoma, all patients
with small cell carcinoma, and anyone with symptoms that could
be related to the presence of brain metastases (e.g. headache,
seizures) [5]. Computed tomography or magnetic resonance
imaging (MRI) of the brain is performed in these situations.
Metastatic spread to the brain is a multi-step process. To
produce brain metastases, tumor cells must: 1. reach the brain
vasculature, 2. attach to the endothelial cells, 3. extravasate into
the parenchyma, 4. proliferate, 5. induce angiogenesis, and 6.
avoid immune surveillance [6]. Thus one might surmise that the
survival and proliferation of metastases to the brain relies on a
healthy and recruitable blood supply. It is generally assumed that
the mechanisms underlying CNS immunoprivilege, the blood-
brain barrier, acts also as a natural barrier to metastases.
Intuitively, one may then predict that a leaky BBB will favor
metastatic recruitment of systemic tumors to the CNS. A leaky
BBB also removes the immunoprivilege. CNS immunoprivilege
may favor metastatic growth; in fact, a recent report has shown that
activation of brain immunity may decrease or delay metastatic
growth [7]. In addition, recent findings have shown that brain-
specific processes allow extravasation of tumor cells across the
intact BBB, thus revealing a unique mechanism that promotes
extravasation under condition of intact vasculature [8]. Finally, a
recent manuscript has shown that a leaky BBB does not necessarily
allow better CNS access for small molecules such as antiepileptic
drugs [9]. Thus, while the BBB is a formidable shield protecting
the brain, its failure does not necessarily lead to complete loss of
function.
Over the past decade, imaging of the brain has improved. We
are now able to identify subclinical vascular changes in the brain,
termed small vessel ischemic disease (SVID). Narrowing of the
vascular lumen and failure of cerebral autoregulation result in
ischemic damage of the cerebral white and subcortical gray matter
[10]. Lacunar brain infarcts and cerebral white matter lesions are
examples of findings related to SVID [11–17]. These lesions are
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associated with an increased risk of stroke, dementia, and
depression [18]. Clinical factors known to increase the risk of
SVID include increased age, hypertension, diabetes mellitus (DM),
hyperlipidemia, and cigarette smoking. Some of these are shared
risk factors for the development of lung cancer.
In a previous study, we found that a large proportion of patients
diagnosed with lung cancer were also found to have SVID on
staging brain MRI [19]. Given the central role of the vasculature
in the development of brain metastases, we aimed to determine if
the presence of SVID was protective against the development of
metastases to the brain of individuals with lung cancer.
Results
A total of 523 patients were enrolled in the study. Data from
phase 1 of the study, including the patients’ demographics and co-
morbidities are summarized in conjunction with the presence and
absence of brain metastases and SVID in Table 1. The criteria for
detection of metastasis is summarized in the Methods section and
exemplified in Figure 1A. The presence of brain metastases was
evaluated after contrast injection. Typically, brain metastases
presented as highly enhancing lesions with variable degree of
perilesional edema. The topographic relationship between meta-
static brain tumors and white matter hyperintensities was also
studied to emphasize that neoplastic lesions rarely occurred in
proximity of primary brain edema presumably pre-existent to the
metastatic invasion.
At the time of lung cancer presentation 109 patients (20.8%)
had evidence of brain metastases on MRI, and 345 (66.0%) were
reported to have evidence of SVID. Individuals without brain
metastases were older (65.3+/210.7 years vs. 62.1+/29.6 years,
p=0.001). There was a trend towards a lower likelihood of brain
metastases in patients with hyperlipidemia (present in 30.4% of
those without metastases vs. 21.1% of those with metastases,
p=0.055) or DM (present in 12.6% of those without metastases vs.
7.3% of those with metastases, p=0.13).
At the time of lung cancer presentation, individuals with SVID
were older (67.269.4 years vs. 59.6610.7 years, p,0.001), more
likely to have a tobacco use history (92.8% in those with SVID vs.
86.5% in those without SVID, p=0.02), and more likely to have
hypertension (47.0% in those with SVID vs. 29.2% in those
without SVID, p,0.0001). There was a trend towards increased
SVID if hyperlipidemia was present (31.0% in those with SVID vs.
23.6% in those without SVID, p=0.07).
Study subjects with brain metastases at presentation were less
likely to have SVID (44.0%) than were those without brain
metastases (71.7%) (p,0.0001, Figure 2). Put another way, 13.9%
of those with SVID and 34.3% of those without SVID presented
with brain metastases (p,0.0001). In a multivariate model that
included age and co-morbidities, the presence of SVID was found
to be the only protective factor against the development of brain
metastases, with an OR of 0.31 (0.20, 0.48; p,0.001). Many brain
metastases (defined as 5 or more) were seen in 27.5% of those with
brain metastases, 34.4% of those without SVID vs. 18.8% of those
with SVID (p=0.07).
In phase 2 of the study, the degree of SVID was graded for
selected study subjects as described in the methods. Two common
radiologic manifestation of SVID is the presence of deep white
matter hyperintensities, periventricular hyperintense signals or
both. Figure 3A shows that those without brain metastases who
were graded for SVID had more SVID (83.0% vs. 68.2%,
p=0.004), and were more likely to have hyperlipidemia (42.0% vs.
26.8%, p=0.005), and be older (69.2610.0 years vs. 64.1610.6
years, p,0.001) than those without brain metastases who were not
graded. Those with brain metastases who were graded for SVID
showed a trend towards a greater frequency of SVID (48.3% vs.
27.3%, p=0.08). They were otherwise statistically similar.
The frequency of SVID grades for deep white matter
hyperintense signals (DWMH), periventricular hyperintense sig-
nals (PVH), and the combination of these two are shown in
Figure 3 for those with and without metastases in whom they were
graded. Those without brain metastases had higher DWMH
grades of SVID (p=0.04), higher PVH grades of SVID (p=0.01),
and higher combination grades of SVID (p=0.02) than those with
brain metastases.
We then focused to the anatomical location of metastases in
SVID positive or negative patients (Figure 3B and Figure 4).
Patients with SVID had, on average, fewer metastases as expected
if a negative correlation exists between SVID and metastatic
tumor. This was true for all the regions where metastases were
measured. in the region where SVID are most common
(cerebrum) there was a statistically significant difference in the
number of metastases as predicted by a protective effect of SVID
against tumor growth. We then measured the severity of SVID in
relation to the presence of metastases. As shown in Figure 4,
patients with metastatic tumors had a much lower SVID score.
Discussion
The main finding of our study is that lung cancer patients with
SVID in the brain have a lower likelihood of having brain
metastases than those without SVID. This was demonstrated by
the following findings: 1) Patients with SVID had a lower
likelihood of presenting with a brain metastasis; 2) SVID was
protective against brain metastases even after controlling for SVID
risk factors (hypertension, age, DM, tobacco use, and hyperlipid-
emia); 3) The higher the grade of SVID, the more protection there
was against presenting with a brain metastasis; and 4) There was a
trend towards those with brain metastases having fewer metastases
if SVID was present. To our knowledge, this is the first report to
describe this relationship.
The reason that brain metastases are less common in those with
SVID is not fully understood. The ‘‘soil and seed’’ theory of
metastases states that a cancer cell must leave its original tumor
location and establish in a hospitable environment for a metastasis
to develop [20]. Thus, a cirrhotic liver would be an unlikely site for
Table 1. Characteristics of lung cancer patients compared









Number 523 109 414 –
Age (mean years,6SD) 64.6+/210.5 62.1+/29.6 65.3+/210.7 0.001
Male Sex (%) 54.5 57.8 53.6 0.44
Tobacco Use (%) 90.6 89.9 90.8 0.77
Diabetes Mellitus (%) 11.5 7.3 12.6 0.13
Hypertension (%) 40.9 37.6 41.8 0.43
Hyperlipidemia (%) 28.5 21.1 30.4 0.055
SVID (%) 66.0 44.0 71.7 ,0.0001
SD=standard deviation, SVID=small vessel ischemic disease.
doi:10.1371/journal.pone.0007242.t001
SVID, Brain Mets & Lung Cancer
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7242Figure 1. Comparison of SVID and metastases by MRI and age: A) Radiologic evaluation of SVID and metastases was based on comparison of post-
contrast and FLAIR images. Note that metastases were obviously demarcated after gadolinium (Gd) injections, while SVID visible in FLAIR were not. The red
circles refer to the locations of SVID or metastases in FLAIR or post-Gd images. B) Age distribution of patients affected by SVID or metastases. Patients with no
metastases were younger than those with metastatic brain tumor; patients with SVID were significantly older than those without small vessel disease.
doi:10.1371/journal.pone.0007242.g001
SVID, Brain Mets & Lung Cancer
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byproducts and inflammatory infiltrates are present that could
interfere with tumor cell growth [21]. There are several aspects of
brain histology and physiology that make it an ideal site for
metastatic growth, while other factors are present that would
prevent metastases from developing. Facilitating factors include
the absence of strong innate and acquired immunity in the brain
parenchyma, the absence of lymphatic drainage, and the
abundant supply of oxygen and glucose. In contrast, the ability
of the blood-brain barrier and the tight junctions of endothelial
cells to isolate the brain from the systemic circulation serves to
protect the brain from developing metastases [22]. One potential
explanation for the protective role of SVID is that the local
immunity in an area of vascular change may be altered. Altered
local immunity could occur if the blood-brain barrier function was
impaired in an area of metastasis-induced neo-vascularization,
allowing enhanced leukocyte, antibody, and complement infiltra-
tion into the area, providing acquired immunity to an organ that
does not normally have it [23]. A second potential explanation of
the protective effect of SVID is that a change in the vascular
architecture may lead to an inability of the cancer cell to
extravasate, receive nutrition, or induce angiogenesis. Changes in
the vascular architecture, such as the changes that occur in the
vascular basement membranes in long-standing DM, may impede
the spread of tumor cells by making the basement membranes less
digestible by tumor cell related proteinases. It has recently been
suggested that DM can protect against metastases in those with
lung cancer [24]. Others have debated a potential survival
advantage in individuals with DM who develop malignancies
[25,26]. Our results point to the vascular changes, rather than the
underlying condition that leads to the vascular changes, as the
reason for protection against brain metastases.
There are potential problems with our study. The retrospective
design influences the accuracy of the data. Though DM,
hypertension, and hyperlipidemia have well known definitions
their listing in the electronic medical record may not have been
entirely accurate or complete. Grading of SVID suggested a
higher prevalence of SVID than was noted on the MRI reports.
The MRI reports may have been less likely to describe SVID
when an obvious metastasis was present or when the SVID was
only very mild. Those with co-morbidities and SVID may be more
likely to receive routine medical care, leading to earlier
identification of their cancer, with a lower likelihood of having a
brain metastasis at presentation. We believe that the strength of
the evidence from multiple lines of reasoning (prevalence of
metastases, number, and relation to grade of SVID) support our
conclusions despite these concerns. Finally, our study only assessed
patients with lung cancer. We cannot conclude that our findings
would apply to other malignancies known to metastasize to the
brain.
A possible confounding aspect of population studies on human
disease is comorbidity. In our population we were able to associate
the presence of SVID to several other factors (diabetes, etc.). This
may lead to a different life span in the subjects, and therefore add
additional variability. We only included brain metastases which
were present and diagnosed at the time of the lung cancer
diagnosis (at initial staging). Since we did not include brain
metastases that developed throughout the course of the patient’s
lung cancer, the fact that those with more comorbidities die earlier
would not influence our results
In conclusion, our findings suggest that vascular changes in the
brain are protective against the development of brain metastases in
lung cancer patients. The use of staging tests and the choice of
treatment relies on the application of clinical and molecular
predictors of risk. Knowledge of the influence of a patient’s
vascular status on risk could be one more factor to consider in the
management of a patient with lung cancer. Determining the
nature of the observed protection will advance our understanding
of lung cancer pathogenesis and provide insights into novel
management strategies.
Materials and Methods
Study Design and Patients
The study was performed with the approval of the Institutional
Review Board (IRB) at the Cleveland Clinic (IRB# 07-698).
Written consent was provided by the patients enrolled in phase 1
of this study. The data obtained from phase 2 of this study was a
retrospective analysis in which the IRB approved a waiver
requiring written patient consent. In the first phase, the medical
records of patients with lung cancer were reviewed. These patients
were identified from two sources. The first group of patients had
enrolled in a prior study that evaluated the diagnostic potential of
serum markers of blood-brain barrier dysfunction in the diagnosis
of cerebral metastases (91 patients) [19]. The second group of
patients was sequential patients seen by a medical oncologist (Dr.
Masaryk; 432 patients) from 6/05-6/07. All patients from both
groups had biopsy proven lung cancer and had undergone MRI
imaging of their brain as part of standard staging. Patients were
not included if they had a history of another cancer diagnosed
within 5 years of their lung cancer presentation (except for non-
melanoma skin cancers and localized prostate cancer). Data
collected included patient demographics, details of the lung
cancer, and risk factors for the development of SVID (DM,
hypertension (HTN), hyperlipidemia, and tobacco use). The
presence of these risk factors was based on a clinical diagnosis
listed in the electronic medical record. MRI reports from the initial
evaluation of the lung cancer were reviewed for the presence of
brain metastases and descriptions of SVID.
In the second phase, MRI scans were re-read under the
guidance of a staff neuroradiologist (TM) with a focus on grading
Figure 2. Pie chart comparison of metastatic and SVID patient
groupings: This figure provides a summary of results on incidence of
metastases in patients affected or not by small vessel ischemic disease.
See text for details.
doi:10.1371/journal.pone.0007242.g002
SVID, Brain Mets & Lung Cancer
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7242Figure 3. SVID grading methods, brain metastases identification, and metastatic distribution: A) Grading for SVID: deep white matter
hyperintense signals, periventricular hyperintensity, and combined. Each represents the SVID distribution of grades of those with and without brain
metastases. Differences were significant for deep white matter hyperintensity (p=0.04), periventricular hyperintensity (p=0.01), and the combined
(p=0.02). B) MRI image with gadolinium contrast demonstrates the protocol used to count identifiable metastases. These are indicated by empty red
circles. C) Distribution of metastases in different CNS regions. Note that in the region where SVID are most common (cerebrum) there was a
statistically significant difference in the number of metastases as predicted by a protective effect of SVID against tumor growth. See text for details.
doi:10.1371/journal.pone.0007242.g003
SVID, Brain Mets & Lung Cancer
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brain had MRI scans available for grading (the other 22 were
outside studies). For those without metastases to the brain, 100
were chosen for grading. These 100 had the lowest medical record
numbers of the group without metastases who had MRI scans
available for review. The grading system used was a combination
of previously described rating scales [27–30]. Periventricular
hyperintensity (PVH) was graded as 0=absence, 1= ‘‘caps’’ or
pencil-thin lining, 2=smooth ‘‘halo,’’ 3=irregular PVH extend-
ing into the deep white matter. Separate deep white matter
hyperintense signals (DWMH) were rated as 0=absence,
1=punctate foci, 2=beginning confluence of foci, 3=large
confluent areas. These scores were analyzed separately and
combined for each patient to give a total burden of SVID score.
Statistical Considerations
Continuous measures were described as means, standard
deviations and percentiles. Categorical measures were summarized
using frequencies and percentages. Wilcoxon Rank Sum tests were
used for the comparison of ordinal measures for binary outcomes.
For the evaluation of association between categorical measures,
Pearson’s Chi-square test of Fisher’s Exact test were used. The
relationships between ordinal measures were evaluated by
Spearman correlation coefficient and Pearson’s correlation
coefficient was used to assess the association between continuous
measures. Logistic regression was performed to assess the
association between ‘SVID grades’ and ‘mets’, after adjusting for
confounding factors. All tests were performed at a significance
level of 0.05. SAS 9.1.3 software (SAS Institute, Cary, NC) was
used for all analyses. Additional statistical analysis was performed
by ANOVA and t-test analysis to determine the influence of age
on propensity toward brain metastasis or SVID.
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